JR Zanchetta is an advisory board member for Merck Inc. and Servier. He has received consultancy fees from Glaxo Smith Kline, Eli Lilly, and Amgen and payment for lectures from Glaxo Smith Kline, Eli Lilly, and Amgen. T Thomas has received research support from Amgen, Chugaï, Merck, Novartis, Pfizer, Roche, Servier, UCB, and Warner-Chilcott; lectured

at national and international meeting symposia funded by Amgen, Genévrier, GSK, Lilly, Merck, and Novartis; and participated in advisory boards for Amgen, Lilly, Merck, Novartis, and UCB. S Boutroy has nothing PF-01367338 order to disclose. C Bogado has nothing to disclose. JP Bilezikian has nothing to disclose. E Seeman has received research support from Amgen, MSD, and Warner Chilcott; lectured at national and international meeting symposia funded by Amgen, Eli Lilly, MSD, and Novartis pharmaceuticals; and has received speaker fees from Amgen, MSD, Novartis, Sanofi-Aventis, and Eli Lilly. E Seeman is one of the inventors of the StrAx1.0 algorithm and a director of Straxcorp. Amgen Inc. sponsored

this study. We are thankful to Michelle N Bradley, PhD for providing formatting and editing support on behalf of Amgen Inc. and Heather Hartley-Thorne for providing graphic support with funding from Amgen Inc. Author JPB received support from NIH grant DK 32333. All authors participated in the design or implementation of the study, and/or the VEGFR inhibitor analysis or interpretation of the findings, and had access to the study data. All authors contributed to the development and critical Montelukast Sodium revision of the manuscript and approved the final version for submission. Author MA accepts primary responsibility for the integrity of the data analysis. “
“The osteopetroses are a group of clinically and genetically heterogeneous

bone diseases sharing the hallmark of increased bone density on radiographs [1]. This pathological feature results from abnormalities in either osteoclast differentiation or function [2]. Clinical and molecular dissection of osteopetroses has identified forms with different severity and prognosis [3], even though classification of single patients into a specific subgroup is not always easy due to the rareness of these conditions and to the presence of a variety of additional clinical features. On the other hand, the possibility to obtain a precise molecular diagnosis importantly impacts on the patients’ management [2] and [3]. Since its first application few years ago [4], [5] and [6], whole exome sequencing has been exploited to identify the causative gene of many monogenic disorders, including skeletal diseases.